中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 1
Jan.  2011

Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection

Research funding:

 

  • Published Date: 2011-01-20
  • More than 170 million people are currently affected by chronic hepatitis C virus (HCV) infection worldwide.Currently, there is no vaccine available.There are many HCV experimental vaccines developed and progressed recently.Here, we would discuss strategies of enhancing immunogenicity of DNA vaccine and review some progress towards development of DNA vaccine against chronic HCV infection.

     

  • [1]Rehermann B, Nascimbeni M.Immunology of hepatitis B virus and hepatitis C virus infection[J].Nat Rev Immune, 2005, 5 (3) :215-229.
    [2]Mannes MP, Wedemeyer H, Cornberg M.Treating viral hepatitis C:efficacy, side effects, and complications[J].Gut, 2006, 55 (9) :1350-1359.
    [3]Houghton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436:961-966.
    [4]Sallberg M, Frelin L, Weiland O.DNA vaccine therapy for chronic hepatitis C virus (HCV) infection:immune control of a moving target[J].Expert Opin Biol Ther, 2009, 9 (7) :805-815.
    [5]Pierre L.Technological advances to increase immunogenicity of DNA vaccines[J].Vaccines, 2002, 1 (1) :85-93.
    [6]Sallberg MM, Frelin L, Diepolder H, et al.A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C[C].Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver, 2009.
    [7]Alvarez-Lajonchere L, Shoukry NH, Gra B, et al.Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial[J].J Viral Hepat, 2009, 16 (3) :156-167.
    [8] Large MK, Kittlesen DJ, Hahn YS.Suppression of host immune response by the core protein of hepatitis C virus:possible implications for hepatitis C virus persistence[J].J Immunol, 1999, 162 (2) :931-938.临床肝胆病杂志2011年第27卷第1期
    [9]Tokushige K, Wakita T, Pachuk C, et al.Expression and immune response to hepatitis C virus core DNA-based vaccine constructs[J].Hepatology, 1996, 24 (1) :14-20.
    [10]Lee SW, Cho JH, Lee KJ, et al.Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses[J].Mol Cells, 1998, 8 (4) :444-451.
    [11]Isaguliants MG, Petrakova NV, Mokhonov VV, et al.DNA immunization efficiently targets conserved functional domains of protease and ATPase/helicase of nonstructural 3 protein (NS3) of human hepatitis C virus[J].Immunol Lett, 2003, 88 (1) :1-13.
    [12]Lang KA, Yan J, Draghia-Akli R, et al.Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine[J].Vaccine, 2008, 26 (49) :6225-6231.
    [13]Jens E, Jasperzu P, Michael G, et al.Proteins of the hepatitis C virus in a response against the nonstructural cellular and humoral immune genetic immunization generates[J].J Immune, 1998, 161 (9) :4917-4923.
    [14]Masalova OV, Lesnova EI, Pichugin AV, et al.The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization[J].Vaccine, 2010, 28 (8) :1987-1996.
    [15]Frelin L, Alheim M, Chen A, et al.Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo[J].Gene Ther, 2003, 10 (8) :686-699.
    [16]Gao M, Wang HP, Wang YN, et al.HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4 (+) Th1 cell responses in vivo[J].Vaccine, 2006, 24 (26) :5491-5497.
    [17]Ma X, Forns X, Gutierrez R, et al.DNA-based vaccination against hepatitis C virus (HCV) :effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice[J].Vaccine, 2002, 20 (27-28) :3263-3271.
    [18]Hong Yu, Lorne A.Babiuk, et al.Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3[J].J Gen Virol, 2004, 85:1533-1543.
    [19]Frelin L, Alheim M, Chen A, et al.Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo[J].Gene Ther, 2003, 10 (8) :686-699.
    [20]Ahlen G, Soderholm J, Tjelle T, et al.In Vivo Ele-ctroporation Enhances the Immunogenicity of Hepatitis C Virus Nonstructural 3/4A DNA by Increased Local DNA Uptake, Protein Expression, Inflammation, and Infiltration of CD3+T Cells[J].J Immunol, 2007, 179 (7) :4741-4753.
    [21]Schwendener RA, Ludewig B, Cerny A, et al.Liposome-based vaccines[J].Methods Mol Biol, 2010, 605:163-175.
    [22]Desjardins D, Huret C, Dalba C, et al.Recombinant retrov-irus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development[J].J Gene Med, 2009, 11 (4) :313-325.
    [23]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.
  • Relative Articles

    [1]Chen Hao, Hao JianHeng, Li ZhenCheng, Xu HuiChao, Gao Yan, Miao YuChuan, Hao HuiQin, Liu Yang. Screening for differentially expressed genes in mice with autoimmune hepatitis and effect of saikosaponin-d on the expression of several differentially expressed genes[J]. Journal of Clinical Hepatology, 2020, 36(4): 840-846. doi: 10.3969/j.issn.1001-5256.2020.04.026
    [2]Shi HaiYan, Li LiYa, He HaoLan, Liu HuiYuan, Chen ZhiMin, Chen WeiLie, Liao BaoLin. Association of HBV precore/core promoter variants with the degree of liver fibrosis in patients with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(5): 1020-1024. doi: 10.3969/j.issn.1001-5256.2018.05.019
    [3]Zhou LianLian, Shen Mo, Zhou Ping, Zhou Wu, Lin XiangYang. HBV genotype distribution and its relationship with serum HBV DNA level and HBeAg expression among patients with chronic hepatitis B in southern Zhejiang Province, China[J]. Journal of Clinical Hepatology, 2014, 30(10): 1039-1041. doi: 10.3969/j.issn.1001-5256.2014.10.016
    [4]Deng Le, Wen ZhiLi. Review of recent research progress in correlating HBV genotypes with efficacy of antiviral treatments[J]. Journal of Clinical Hepatology, 2012, 28(6): 469-473.
    [5]Yang YanLin, Xiao Ping, Gao Peng, Wang LiMing, Wei XiSheng, He Qiang, Zhou Ping. Distribution of HBV genotypes and YMDD mutations in E antigen-positive patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 428-430.
    [6]Guo XinHui, Yan Yan, Li Zhuo, Yin JiMing. Fluorescent reverse transcription-PCR assay for determination of hepatitis C virus genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 65-67.
    [7]Cheng Ling, Hong GuoHu, Guo Yan, Mao Qing. Prediction of HLA-DRB1*0311/0401 in recognizing epitopes of HCV Core protein of different genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 61-64.
    [8]Liu JinPing, Liu YouDe, Guo YanMei, Yang ShaoPing, Lin Qing, Lin Ling. Clinical characteristics and distribution of hepatitis B virus genotypes in CHB patients in Yantai area[J]. Journal of Clinical Hepatology, 2011, 27(12): 1288-1290.
    [9]Zhang WenJie, Liu LiJun, Du ShaoCai, Li ChaoXia, Lu QingYun, Yang ShaoHua. The prevalence of hepatitis C virus genotype in Lanzhou area[J]. Journal of Clinical Hepatology, 2010, 26(3): 290-291+294.
    [10]Wang GuoQiang, Niu JuXia. The HBx protein mutation among different HBV genotypes[J]. Journal of Clinical Hepatology, 2010, 26(4): 392-394.
    [12]Li Jun, Chen XinYue, Zhao Hong, Yu YanYan, Si ChongWen, Han ZhongHou, Zhang WenJin, Chen YuPing, Chen Yong, Wang GuiQiang, Yu Min, Gong WeiBo, Xu JingHang, Wang Jun, Lin XiaoHong, Li XueYing. The relationship of hepatitis B virus genotypes and efficacy of lamivudine and interferon alpha 2b in the treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(3): 169-171.
    [13]Xiao Yang, Hu CaoHan, Zhou YueJin, Xie QingRong, Zhu BingXing, Hu Xia, Wang KaiJian, Zhang WenJing. Effect of hepatitis B virus genotypes on response to interferon α2b in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2006, 22(2): 105-106.
    [15]Liu ChengYong, Hou YuanPei, Qian XiuMei, Sun Qing, Song Li. Distribution of hepatitis B virus genotype in Xuzhou and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(3): 151-152.
    [16]Li TingMing, Zhu YouFu, He HaiTang, Mao QianGuo, Wu AiHua, Liang YuFang, Luo KangXian. The relation between chinese hepatitis B virus genotype B C and efficacy of interferon-α.[J]. Journal of Clinical Hepatology, 2005, 21(1): 16-18.
    [17]Xu ZhengJu, Yang Hong, Zhang QiHua, Chen XianLi, Li ShuQing, Wang ChongGuo. Study on the relationship between hepatitis B virus genotypes and effect of lamivudine therapy.[J]. Journal of Clinical Hepatology, 2005, 21(3): 157-159.
    [18]Jiao Jian, Wang JiangBin. Distribution of HCV genotypes and its clinical features in patients coinfected with HCV and HBV[J]. Journal of Clinical Hepatology, 2004, 20(2): 75-76.
    [19]Lu YinYing, Wang Lin, Liu Yan, Li Ke, Cheng Jun, Zhang LingXia, Li Li. Cloning and expression of gene of hepatitis B virus e antigen in yeast[J]. Journal of Clinical Hepatology, 2003, 19(3): 166-168.
    [20]Yao Gang, Zhang Lian, Bao LiHua. HBV genotypes and efficacy of interferon-α on patients with chronic hepatitis B.[J]. Journal of Clinical Hepatology, 2002, 18(5): 273-274.
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.1 %FULLTEXT: 3.1 %META: 93.5 %META: 93.5 %PDF: 3.4 %PDF: 3.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.8 %其他: 4.8 %其他: 0.5 %其他: 0.5 %China: 0.3 %China: 0.3 %[]: 0.8 %[]: 0.8 %上海: 3.7 %上海: 3.7 %北京: 6.6 %北京: 6.6 %北海: 0.8 %北海: 0.8 %南京: 0.8 %南京: 0.8 %南宁: 0.8 %南宁: 0.8 %厦门: 0.3 %厦门: 0.3 %台州: 0.5 %台州: 0.5 %吉林: 0.5 %吉林: 0.5 %呼和浩特: 0.5 %呼和浩特: 0.5 %哥伦布: 0.3 %哥伦布: 0.3 %宁波: 0.3 %宁波: 0.3 %宿迁: 1.6 %宿迁: 1.6 %常州: 0.3 %常州: 0.3 %张家口: 1.6 %张家口: 1.6 %新乡: 2.1 %新乡: 2.1 %无锡: 0.3 %无锡: 0.3 %杭州: 0.8 %杭州: 0.8 %武汉: 0.3 %武汉: 0.3 %淮安: 0.3 %淮安: 0.3 %深圳: 1.1 %深圳: 1.1 %渭南: 0.3 %渭南: 0.3 %玉林: 0.5 %玉林: 0.5 %石家庄: 0.5 %石家庄: 0.5 %芒廷维尤: 26.1 %芒廷维尤: 26.1 %苏州: 0.3 %苏州: 0.3 %莫斯科: 0.8 %莫斯科: 0.8 %西宁: 30.6 %西宁: 30.6 %贵港: 1.6 %贵港: 1.6 %郑州: 8.5 %郑州: 8.5 %长春: 0.5 %长春: 0.5 %阿布奎基: 0.3 %阿布奎基: 0.3 %黄冈: 0.3 %黄冈: 0.3 %其他其他China[]上海北京北海南京南宁厦门台州吉林呼和浩特哥伦布宁波宿迁常州张家口新乡无锡杭州武汉淮安深圳渭南玉林石家庄芒廷维尤苏州莫斯科西宁贵港郑州长春阿布奎基黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (3318) PDF downloads(910) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return